drugset

drugset / Trial / NCT00420381

Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer

NCT00420381 ↗

Phase 2 Completed 28 enrolled Eli Lilly and Company Gynecologic Oncology Group · collab

NaSequentialOpen-labelTreatment

Summary

The purpose is to assess the efficacy and toxicity of the study agent, enzastaurin, in participants with recurrent or persistent ovarian cancer.

Timeline

Start: 2007-01
Primary completion: 2008-05
Completion: 2014-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	enzastaurin	Small molecule	500 mg	Oral

Indications